ライフサイエンスコーパス: losartan

1 the Ang II type 1 (AT1) receptor antagonist losartan.

2 levels and these effects were not blocked by losartan.

3 ment with the Ang II type 1 receptor blocker losartan.

4 ith the addition of either spironolactone or losartan.

5 , +10.5%, P = 0.20) in the group assigned to losartan.

6 ime costs for aliskiren plus losartan versus losartan.

7 II accumulation induced by hyperglycemia and losartan.

8 angiotensin II in the absence or presence of losartan.

9 The crossover also included amiloride and losartan.

10 chronic intracerebroventricular delivery of losartan.

11 ntions were used; isoflurane anaesthesia and losartan.

12 as managed with prednisone, alendronate, and losartan.

13 ial that assessed renoprotective efficacy of losartan.

14 pressor response of 25.5 mg/kg) relative to losartan.

15 mized to daily receive losartan 100 mg or no losartan.

16 he angiotensin II type 1 receptor antagonist losartan.

17 losartan, 1.8+/-1.5 mm/3 years, n=21 versus losartan 0.5+/-0.8 mm/3 years, n=17; P=0.001) and not in

18 losartan, 1.2+/-1.7 mm/3 years, n=38 versus losartan 0.8+/-1.3 mm/3 years, n=41; P=0.197).

19 losartan, 1.3+/-1.5 mm/3 years, n=59 versus losartan, 0.8+/-1.4 mm/3 years, n=58; P=0.009).

20 versus Ang II); adding the AT(1) antagonist losartan (1 microm) resulted in Ang II stimulating NO by

21 Further, the AT1 R blocker losartan (1 mum) diminished myogenic tone and blocked st

22 Dose-ranging studies of losartan (1-50 mg/kg) were initially conducted in a rat

23 Captopril alone (1.78 +/- 0.31%) and with losartan (1.13 +/- 0.28%) significantly reduced tracer u

24 ment with an Ang II type 1 receptor blocker (losartan, 1 micromol/l), calcineurin inhibitor (cyclospo

25 1) and not in dominant negative patients (no losartan, 1.2+/-1.7 mm/3 years, n=38 versus losartan 0.8

26 ntly reduced aortic root dilatation rate (no losartan, 1.3+/-1.5 mm/3 years, n=59 versus losartan, 0.

27 ation rate in haploinsufficient patients (no losartan, 1.8+/-1.5 mm/3 years, n=21 versus losartan 0.5

28 ensive effects of the AT(1) receptor blocker losartan (10 mg/kg/day) were attenuated by ~15 mm Hg.

29 sive effects of cediranib were unaffected by losartan (10 mg/kg/h), bosentan (20 mg/kg/h), or a combi

30 sive effects of cediranib were unaffected by losartan (10 mg/kg/h), bosentan (20 mg/kg/h), or a combi

31 renal arterial myocytes, the AT1R antagonist losartan (10 muM) abolished the ANG-II (1 muM)-induced r

32 Losartan (10(-10) to 10(-6)M) was further tested ex vivo

33 an patients were randomized to daily receive losartan 100 mg or no losartan.

34 dex >25 kg/m(2) to receive aliskiren 300 mg, losartan 100 mg, or their combination daily for 9 months

35 ia and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or pla

36 e randomly assigned the patients to placebo, losartan (100 mg daily), or spironolactone (25 mg daily)

37 ndomly assigned via computer-based system to losartan (100 mg per day) or placebo for 12 months.

38 , 1.11-1.73, respectively); use of high-dose losartan (100 mg) was similar in risk (HR, 0.71; 95% CI,

39 ssigned 153 transplant recipients to receive losartan, 100 mg (n=77), or matching placebo (n=76) with

40 abetic nephropathy, addition of aliskiren to losartan, 100 mg resulted in a 20% greater reduction in

41 Among 4397 users of losartan, 1212 deaths occurred during 11,347 person-year

42 e (ACE) inhibitors were randomly assigned to losartan 150 mg (n=1927) or 50 mg daily (n=1919).

43 Losartan 150 mg daily reduced the rate of death or admis

44 ian follow-up in each group (IQR 3.7-5.5 for losartan 150 mg; 3.4-5.5 for losartan 50 mg), 828 (43%)

45 Patients were randomly assigned between losartan (150 mg daily) and placebo with target treatmen

46 placebo group; the incidence was higher with losartan (17%, P=0.01 by the log-rank test) but not with

47 The AT1 receptor antagonist losartan (2 microm, n = 6) abolished all responses to An

48 Muscimol (80 pmol), a GABA(A) agonist, or losartan (43.4 pmol), an AT(1) receptor antagonist, atte

49 intolerance to ACE inhibitors compared with losartan 50 mg daily.

50 IQR 3.7-5.5 for losartan 150 mg; 3.4-5.5 for losartan 50 mg), 828 (43%) patients in the 150 mg group

51 6-32 mg), low-dose (12.5 mg) and medium-dose losartan (50 mg) were associated with increased mortalit

52 with an angiotensin II receptor antagonist, losartan, 50 mg daily.

53 o: Nx+V receiving vehicle; Nx+L treated with losartan, 50 mg/kg/day; Nx+L+Eple, given losartan and ep

54 g the higher pharmacy costs of aliskiren and losartan ($7769), which were partially offset by savings

55 oint evaluation of Angiotensin II Antagonist Losartan), a multinational randomized trial in symptomat

56 the cognitive and cerebrovascular rescue of losartan, a commonly prescribed ARB, in a mouse model of

57 Losartan, a commonly prescribed US Food and Drug Adminis

58 We propose losartan, a drug approved by the US Food and Drug Admini

59 We tested whether losartan--a clinically approved angiotensin II receptor

60 The selective AT1 receptor blocker (ARB) losartan abrogated aneurysm progression in the mice; ful

61 Moreover, losartan activated Smad7 protein, a key negative regulat

62 s no increased mortality comparing high-dose losartan against the highest doses of candesartan.

63 s not significantly different from that with losartan alone (P=0.52).

64 Treatment with enalapril or losartan also decreased renal plasminogen activator inhi

65 Losartan also suppressed tumor necrosis factor alpha gen

66 antibody to all three isoforms of TGF-beta), losartan (an angiotensin receptor antagonist), or a comb

67 vealed it to be insensitive to inhibition by losartan (an AT(1) receptor antagonist) and PD123319 (an

68 is, which was abrogated by co-treatment with losartan (an AT-1R antagonist), wortmannin (a phosphoino

69 henotype of RenTgMK mice, and treatment with losartan [an angiotensin type 1 receptor blocker (ARB)]

70 phy that can be attenuated by treatment with losartan, an angiotensin II (AngII) type 1 receptor bloc

71 rrent study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulm

72 ed ligand of the angiotensin II receptor, or losartan, an angiotensin II receptor blocker.

73 Treatment of diabetic ZDF rats with losartan, an angiotensin II receptor-1 (Agtr1) antagonis

74 Recent evidence suggests that losartan, an angiotensin II type 1 blocker that blunts T

75 l muscle remodeling following treatment with losartan, an angiotensin II type I receptor blocker.

76 angiotensin-converting enzyme inhibitors or losartan, an angiotensin receptor blocker, will decrease

77 Use of losartan, an angiotensin receptor type 1 blocker used wi

78 features were prevented by co-injection with losartan, an AT(1) receptor antagonist, or by an antibod

79 Losartan, an AT1 receptor antagonist, and inhibitors of

80 nt occurred in 6 of 47 patients who received losartan and 12 of 44 who received placebo (odds ratio [

81 New users of losartan and candesartan were selected for inclusion in

82 By life table analysis, we found that losartan and doxycycline improved the survival of Fbn1(m

83 of MMP-2 in MFS and compared the effects of losartan and doxycycline on aortic dilatation and surviv

84 ith losartan, 50 mg/kg/day; Nx+L+Eple, given losartan and eplerenone, and Nx+L+Ly, given losartan and

85 s were diminished in animals pretreated with losartan and in those deficient for the ATII receptor 1a

86 losartan and eplerenone, and Nx+L+Ly, given losartan and Ly.

87 f 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces al

88 In conclusion, adding aliskiren to losartan and optimal therapy in patients with type 2 dia

89 ney injury; however, combined treatment with losartan and paricalcitol completely prevented albuminur

90 application of the AT(1) receptor antagonist Losartan and subsequent pre-collicular transection (to r

91 otensin-II (A-II) type 1 receptor antagonist losartan and the nonspecific A-II receptor antagonist sa

92 ere inhibited by the AT1 receptor antagonist losartan and the phospholipase C (PLC) inhibitor U73122.

93 of the angiotensin type 1 receptor blockers losartan and valsartan and the angiotensin-converting en

94 OSA group, all subjects continued to receive losartan and were randomly assigned to either nightly CP

95 12 patients receiving enalapril, 6 receiving losartan, and 4 receiving placebo.

96 y the angiotensin II type 1 receptor blocker losartan, and by the NADPH oxidase inhibitor apocynin.

97 and 5.8 g/m(2) reductions in the aliskiren, losartan, and combination arms, respectively; P<0.0001 f

98 BP was determined in DHI, Losartan, and placebo- treated Spontaneously Hypertensiv

99 inhibitor, the angiotensin-receptor blocker losartan, and their combination on the reduction of LV m

100 Losartan (angiotensin type 1 receptor (AT1) antagonist)

101 (angiotensin-converting enzyme inhibitor) or losartan (angiotensin-receptor blocker) in FSGS mice sti

102 Young (3-month-old) mice were treated with losartan ( approximately 10 mg/kg/d, 4 months), followed

103 baseline to follow-up in the combination and losartan arms; the secondary objective was to determine

104 red smooth muscle cells (SMC) was reduced by losartan, as was SMC invasion through an elastin gel bar

105 Methods We provided losartan (at a dose of 100 mg per day) to patients with

106 s PD123319 (AT(2)R blocker), or insulin plus losartan (AT(1)R blocker, intravenously).

107 reatment with aliskiren (renin inhibitor) or losartan (AT1 antagonist) ameliorated pulmonary ECM depo

108 reated in a blinded manner with atenolol- or losartan-based regimens.

109 in MFS and decrease after administration of losartan, beta-blocker therapy, or both and therefore mi

110 The AT1R antagonist losartan blocked AngII-induced, but not vasopressin-indu

111 ct, the removal of Tgfbr2 and treatment with losartan both delayed the progression of articular carti

112 (18)F-FPyKYNE-losartan bound with high affinity (dissociation constant

113 was blocked by the selective AT1R antagonist losartan but not by the selective AT2R antagonist PD1233

114 reased by >50% with insulin and insulin plus losartan but not with insulin plus PD123319.

115 an angiotensin II (AT)1 receptor antagonist (losartan), but not by an AT2 receptor blocker (PD123319)

116 ndpoints, 1D11 was equivalent or superior to losartan; coadministration of the two agents was not sup

117 rated a significantly attenuated response to losartan compared to sham animals but showed no greater

118 patients with heart failure, overall use of losartan compared with candesartan was not associated wi

119 rmin in combination versus rosiglitazone and losartan, compared to rosiglitazone alone, after 48 week

120 glitazone and metformin or rosiglitazone and losartan confers no greater benefit than rosiglitazone a

121 Next, we examined whether losartan could improve impaired responses of cerebral ar

122 cluded patients, 47 patients received 150 mg losartan daily (age, 38.0+/-12.4 years; 74% male), and 4

123 roduction in nondiabetics and diabetics, and losartan decreased basal (diabetics) and angiotensin II-

124 gnaling, with the ATII receptor 1a inhibitor losartan, decreased LPS-induced pulmonary neutrophil rec

125 Losartan delayed disease progression, decreased right ve

126 In addition, while losartan did not alter responses in nondiabetics, losart

127 Losartan did not block the antihypertrophic effects of A

128 In predefined subgroup analyses, losartan did not have a statistically significant impact

129 Furthermore, losartan did not increase cAMP in HEK 293a cells express

130 In conclusion, treatment with losartan did not lead to a statistically significant red

131 Losartan did not significantly improve RV EF in comparis

132 inopril, or angiotensin II receptor blocker, losartan, did not improve cell engraftment.

133 Enalapril and losartan each reduced hypertension, proteinuria, glomeru

134 miR-29b levels, whereas TGF-beta blockade or losartan effectively decreased miR-29b levels in Fbn1(C1

135 This study investigates losartan effectiveness in genetically classified subgrou

136 tment with the angiotensin type 1 antagonist losartan eliminated the difference in obstruction-induce

137 ing, both acute and 2-week administration of losartan enhanced the consolidation of extinction memory

138 rivative of the clinically used AT1R blocker losartan exhibits high binding selectivity for kidney AT

139 In contrast, in DH rats, Losartan, followed by pre-collicular and pontine transec

140 mice were treated with the AngII antagonist losartan for 12 wk.

141 brain were also altered in mice treated with losartan for 2 weeks, in particular reduced amygdala AT1

142 mice were treated with the Tgfbr2 inhibitor losartan for 8 weeks and then euthanized for collection

143 FPyKYNE-losartan fully antagonized the Ang II pressor effect, al

144 ificantly between the atenolol group and the losartan group (-0.139+/-0.013 and -0.107+/-0.013 standa

145 d the enalapril group (0.005, P=0.38) or the losartan group (0.026, P=0.26), nor were there significa

146 A decrease in systolic blood pressure in the losartan group (from mean 127 mm Hg [SD 12] to 121 mm Hg

147 cular mass between the placebo group and the losartan group (mean difference 1 g/m(2), 95% CI -3 to 6

148 e atenolol group and 11.0+/-6.2 years in the losartan group), who had an aortic-root z score greater

149 nd 0.29, 95% CI, 0.16-0.52; P < 0.001 in the losartan group).

150 assigned to the metoprolol group, 102 to the losartan group, and 110 to the control group.

151 In the losartan group, one (1%) patient had angioedema, one (1%

152 en group; 5.5+/-15.6/3.7+/-10.7 mm Hg in the losartan group; 6.6+/-16.6/4.6+/-10.5 mm Hg in the combi

153 as significantly lower in the metoprolol and losartan groups compared with the control group [6%, 12%

154 difference was found when the metoprolol and losartan groups were directly compared (P = 0.21).

155 Use of Losartan had dramatically beneficial effects on sarcopen

156 The local Ang II receptor (AT1R) blocker losartan had negligible effect on tone or [Ca(2+)]i in c

157 Losartan had no significant effect on RV dysfunction or

158 (18)F-FPyKYNE-losartan has a favorable binding profile and displays hi

159 Losartan has been shown to prevent aneurysms in another

160 Thus, losartan has the potential to enhance the efficacy of na

161 Losartan, HET0016, and 20-HETE antagonists each normaliz

162 armacologic inhibition using AT1R antagonist losartan, HGF and HPLF were stimulated by IL-1beta for 3

163 ment at both 2 and 9 months of age, whereas, losartan improved grip strength only at 2 months.

164 Furthermore, losartan improved the distribution and therapeutic effic

165 Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, t

166 The ARB was losartan in 17 patients and irbesartan in 1 patient.

167 etion of IL-6 and IL-8 was not influenced by losartan in HGF or HPLF.

168 Aliskiren was as effective as losartan in promoting LV mass regression.

169 ing assays were performed with (18)F-FPyKYNE-losartan in rat kidneys.

170 ly attenuated the antihypertensive effect of losartan in rats with renal hypertension.

171 Aliskiren was as effective as losartan in reducing LV mass index (P<0.0001 for noninfe

172 termine whether aliskiren was noninferior to losartan in reducing LV mass index from baseline to foll

173 determine whether there might be a role for losartan in specific vulnerable subgroups.

174 al volume was lower in subjects treated with losartan in the microalbuminuria group (18.8 vs. 25.6%;

175 t angiotensin II (AngII) and inverse agonist losartan in wild-type AT1R changed the accessibility of

176 nic effects of an AT(1) receptor antagonist (losartan) in the monocrotaline PAH rat model (60 mg/kg).

177 d an angiotensin II type 1 receptor blocker (losartan) in thymic stromal lymphopoietin transgenic (TS

178 cells that express endogenous AT1R and D1R, losartan increased cAMP generation.

179 Losartan increased cAMP in HEK 293a cells transfected wi

180 We found that adding aliskiren to losartan increased time free of ESRD, life expectancy, a

181 with either receptor alone, suggesting that losartan induces D1R activation.

182 AP on the cardiovascular effects of chronic losartan infusion in order to test the hypothesis that a

183 Losartan inhibited acute joint inflammation in a dose-de

184 We found that losartan inhibited collagen I production by carcinoma-as

185 Administration of losartan inhibited TGF-beta signaling pathway, resulting

186 ]-AngII, but not the neutral AT1 antagonist, losartan, inhibits endogenous B2 receptor signaling.

187 er prophylactic treatment with metoprolol or losartan, initiated soon after lung cancer surgery in pa

188 A prophylactic treatment with metoprolol or losartan, initiated soon after lung cancer surgery in pa

189 409 hypertensive patients in the LIFE study (Losartan Intervention For End-point reduction in hyperte

190 In the Losartan Intervention for Endpoint Reduction (LIFE) echo

191 eline electrocardiogram, and enrolled in the Losartan Intervention for Endpoint Reduction in Hyperten

192 Injections of losartan into the LV blocked the dipsogenic response to

193 Chronic inhibition of RAAS by losartan is beneficial in experimental PAH.

194 Losartan is exceptional amongst antihypertensive drugs i

195 mediated platelet aggregation as compared to losartan (LOS) (collagen, IC50 = 10.4 muM; CRP-XL, IC50

196 evaluate the effect of Telmisartan (Tel) and Losartan (Los) on nanoparticle intratumoral distribution

197 neal injections of TNF (30 microg/kg), TNF + losartan (LOS, 1 mg/kg), or vehicle for 5 days.

198 As an add-on to losartan, Ly normalized blood pressure and albuminuria,

199 ults from observational studies suggest that losartan may be associated with increased mortality in p

200 h regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the c

201 knockdown and AT1R pharmacologic blockade by losartan may differently control balance of inflammatory

202 Treatment with losartan may preserve some features of kidney structure

203 i-inflammatory effects, but failed to modify losartan-mediated reductions in oxidative stress.

204 Inhibition by an AT1 receptor antagonist (losartan metabolite: E3174) or catalase, confirmed that

205 %), and central antagonism of AT1 receptors (losartan) microinjected into the lateral ventricle reduc

206 Taken together, these data imply that losartan might exert its antihypertensive effect both by

207 Pharmacologic inhibition of AT1R through losartan modulated mRNA transcription of IL-6 and IL-8 i

208 s not significantly different from that with losartan monotherapy, independent of blood pressure lowe

209 MFS patients treated with losartan (n=55) or beta-blocker (n=80) showed significan

210 were randomly assigned to placebo (n=69) or losartan (n=64).

211 Neither losartan nor divalinal affected arterial blood pressure

212 d blockade of the ANGII receptor type 1 with losartan normalizes BP.

213 r the angiotensin II type 1 receptor blocker losartan normalizes muscle architecture, repair and func

214 interval [CI], 0.14 to 0.85) and by 70% with losartan (odds ratio, 0.30; 95% CI, 0.12 to 0.73), indep

215 red the effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart fai

216 ffect of the angiotensin II receptor blocker losartan on left ventricular hypertrophy and fibrosis in

217 ever, the role of MMP-2 in MFS and effect of losartan on the lifespan of MFS mice remain unknown.

218 We found no significant effect of losartan on time to a composite of ESRD, death, or doubl

219 the effect of the AngII receptor antagonist, losartan, on the drinking response to AngII injected int

220 mg of rosiglitazone twice-daily and 50 mg of losartan once-daily for 48 weeks.

221 ty, which was abolished by co-treatment with losartan or 2',5'-dideoxyadenosine (2',5'-DOA, an adenyl

222 placental apoptosis are diminished by either losartan or an autoantibody-neutralizing peptide.

223 fan's syndrome who were randomly assigned to losartan or atenolol, we found no significant difference

224 Treatment of the diabetic mice with losartan or paricalcitol (19-nor-1,25-dihydroxyvitamin D

225 Subjects received 100 mg losartan or placebo daily.

226 ) /dy(2J) and control mice were treated with losartan or placebo for 12 weeks from 6 weeks of age.

227 locked by an antagonist of AngII receptor I, losartan, or overexpression of single mutant S303A of IR

228 ne were randomized to a mean of 4.8 years of losartan- or atenolol-based treatment.

229 line electrocardiogram, randomly assigned to losartan- or atenolol-based treatment.

230 ed with renin-angiotensin system inhibition (losartan plus enalapril).

231 In contrast, losartan plus insulin increased muscle MBV by two- to th

232 tments with either isoflurane anaesthesia or losartan prevented early microvascular damage and late e

233 etes, but treatment with either captopril or losartan prevented these effects.

234 Most importantly, losartan prevents the development of delayed recurrent s

235 e angiotensin II type 1 receptor antagonist, losartan, previously identified as a blocker of peripher

236 nt a novel combinatorial treatment utilizing losartan, previously shown to ameliorate fibrosis and in

237 Losartan reduced BP in OSA, but the reductions were less

238 Treatment with losartan reduced left ventricular dysfunction and preven

239 However, losartan reduced only aortic root dilatation rate in hap

240 It has been shown that losartan reduces aortic dilatation in patients with Marf

241 Consequently, losartan reduces solid stress in tumours resulting in in

242 e demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan product

243 in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial with independent replication in

244 The mechanism depicting how ARBs such as losartan restore cerebrovascular and cognitive deficits

245 tan did not alter responses in nondiabetics, losartan restored impaired eNOS-dependent vasodilatation

246 Divalinal reverted losartan's anti-inflammatory effects, but failed to modi

247 /AT4R cascade as the underlying mechanism in losartan's benefits and a target that could restore Abet

248 Here, we propose a mechanism underlying losartan's benefits by selectively blocking the effects

249 scue spatial learning and memory and blocked losartan's benefits on dilatory function and baseline ni

250 Divalinal countered losartan's capacity to rescue spatial learning and memor

251 animals but showed no greater attenuation of losartan's chronic hypotensive effects than animals with

252 Losartan's effects on transforming growth factor beta (T

253 In a secondary analysis, losartan seemed to reduce the risk of a composite of dou

254 Finally, the prototypic AT(1)R antagonist losartan seems unable to lower this adrenal betaarr1-dri

255 e to the angiotensin receptor type 1 blocker losartan showed decreased JNK phosphorylation.

256 Overall, losartan significantly reduced aortic root dilatation ra

257 Losartan significantly reduced systolic, diastolic, and

258 In this study, the AT1R antagonist losartan strengthened the interaction between AT1R and D

259 nd therapeutic administration of 15 mg/kg of losartan substantially reduced knee joint swelling in ra

260 njected into 4V, even when we used a dose of losartan that was 25 times greater than needed when inje

261 he angiotensin II type 1 receptor antagonist losartan, the oxytocin receptor antagonist desGly-NH2 ,

262 FBN1 mutations seem to be more responsive to losartan therapy for inhibition of aortic root dilatatio

263 he angiotensin II type 1 receptor antagonist losartan to mutation-positive, hypertrophy-negative (pre

264 ion, the addition of spironolactone, but not losartan, to a regimen including maximal ACE inhibition

265 Losartan-treated Fbn1(C1039G/+) mice had lower total TGF

266 oved cardiac structure and function, whereas losartan-treated mice had no improvement.

267 Overall, enalapril- and losartan-treated TSLPtg mice survived significantly long

268 Losartan treatment did not reverse pathologic remodeling

269 Inhibition of TGFbeta signaling by Losartan treatment greatly improved the phenotype of myo

270 s study support pursuing a clinical trial of losartan treatment in children with MDC1A.

271 We therefore evaluated the effect of losartan treatment in the dy(2J) /dy(2J) mouse model of

272 In addition, losartan treatment inhibited the MAPK cascade as shown b

273 Losartan treatment was associated with significant impre

274 After losartan treatment, we performed classical Pavlovian fea

275 Losartan treatment, which lowers TGFbeta signaling and r

276 sing Morris water mazes at 3 and 4 months of losartan treatment.

277 r-beta (TGFbeta) signaling in the aorta, but losartan uniquely inhibited TGFbeta-mediated activation

278 vely; 8 received captopril or captopril with losartan up to 4 weeks after MI.

279 s was affected for generic versus brand-name losartan users only (difference of proportions, 2.0% [0.

280 Rates of adverse events for losartan, valsartan, and candesartan users (N=136 177) a

281 Among generic users of losartan, valsartan, and candesartan, there was an incre

282 years, and lifetime costs for aliskiren plus losartan versus losartan.

283 FR outcome, and the unadjusted hazard ratio (losartan vs. placebo) was 0.50 (95% CI, 0.12-1.99).

284 FS mutant mice (Fbn1(C1039G/+)) treated with losartan was analyzed for circulating TGF-beta1 concentr

285 However, in a post hoc analysis, losartan was associated with improved RV EF in a subgrou

286 The angiotensin receptor blocker losartan was given to half the animals.

287 There was no effect, however, when losartan was injected into 4V, even when we used a dose

288 Compared with candesartan, losartan was not associated with increased all-cause mor

289 mass with the combination of aliskiren plus losartan was not significantly different from that with

290 Treatment with losartan was safe, suggesting that it can be used for ot

291 angiotensin receptor type 1 (AT1) antagonist losartan, we investigated the acute and long-term effect

292 Although low doses of losartan were associated with increased mortality, there

293 d heart rate responses to 10-day infusion of losartan were compared in sham rats and those with dual

294 Conversely, irbesartan and losartan were largely G protein-selective inhibitors at

295 retreated with the conventional AT1R blocker losartan were unable to enhance cardiac contractility wi

296 Administration of losartan, which blocks all type 1 angiotensin receptors,

297 l of the selective AT(1) receptor antagonist losartan, which is currently used for the treatment of c

298 We conducted a randomized trial comparing losartan with atenolol in children and young adults with

299 ombining angiotensin II receptor blockade by losartan with beta-blocker treatment is an effective tre

300 er attenuation of the hypotensive effects of losartan would be observed in rats with dual lesions.